KR940005273A - 퀴놀린 및 퀴나졸린 유도체를 함유하는 약학적 조성물 및 그의 신규 화합물 - Google Patents

퀴놀린 및 퀴나졸린 유도체를 함유하는 약학적 조성물 및 그의 신규 화합물 Download PDF

Info

Publication number
KR940005273A
KR940005273A KR1019930006930A KR930006930A KR940005273A KR 940005273 A KR940005273 A KR 940005273A KR 1019930006930 A KR1019930006930 A KR 1019930006930A KR 930006930 A KR930006930 A KR 930006930A KR 940005273 A KR940005273 A KR 940005273A
Authority
KR
South Korea
Prior art keywords
compound
ring
optionally substituted
salt
dimethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019930006930A
Other languages
English (en)
Korean (ko)
Inventor
다까시 소오다
하루히꼬 마끼노
아쯔오 바바
Original Assignee
모리따 가쯔라
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모리따 가쯔라, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 모리따 가쯔라
Publication of KR940005273A publication Critical patent/KR940005273A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C07D239/76—N-oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1019930006930A 1992-04-24 1993-04-24 퀴놀린 및 퀴나졸린 유도체를 함유하는 약학적 조성물 및 그의 신규 화합물 Ceased KR940005273A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP10642492 1992-04-24
JP92-106424 1992-04-24
JP12188792 1992-05-14
JP92-121887 1992-05-14
JP28586592 1992-10-23
JP92-285865 1992-10-23
JP93-37952 1993-02-26
JP3795293 1993-02-26

Publications (1)

Publication Number Publication Date
KR940005273A true KR940005273A (ko) 1994-03-21

Family

ID=27460501

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930006930A Ceased KR940005273A (ko) 1992-04-24 1993-04-24 퀴놀린 및 퀴나졸린 유도체를 함유하는 약학적 조성물 및 그의 신규 화합물

Country Status (14)

Country Link
US (1) US5948782A (enExample)
EP (1) EP0567107B1 (enExample)
KR (1) KR940005273A (enExample)
CN (1) CN1079222A (enExample)
AT (1) ATE209199T1 (enExample)
AU (1) AU656069B2 (enExample)
CA (1) CA2094774A1 (enExample)
DE (1) DE69331171T2 (enExample)
FI (1) FI931855A7 (enExample)
HU (2) HUT64322A (enExample)
NO (1) NO305973B1 (enExample)
NZ (1) NZ247477A (enExample)
RU (1) RU2130934C1 (enExample)
TW (1) TW232013B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455253A (en) * 1992-10-20 1995-10-03 Zeneca Limited Heterocyclic derivatives
NO940245D0 (no) * 1993-01-28 1994-01-24 Takeda Chemical Industries Ltd Quinolin eller quinazolinderivater, deres fremstilling og anvendelse
ATE169924T1 (de) * 1993-05-18 1998-09-15 Takeda Chemical Industries Ltd Benzopyran-derivate und ihre verwendung
DE69422450T2 (de) * 1993-06-29 2000-06-08 Takeda Chemical Industries, Ltd. Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
AU698625B2 (en) * 1993-11-12 1998-11-05 Pharmacia & Upjohn Company Pyrimidine-thioalkyl and alkylether compounds
US5650410A (en) * 1994-03-08 1997-07-22 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing quinoline or quinazoline derivatives and derivatives therefor
US5641788A (en) * 1994-06-07 1997-06-24 Takeda Chemical Industries, Ltd. Quinoline derivatives and pharmaceutical composition containing them
WO1996033717A1 (en) * 1995-04-28 1996-10-31 Takeda Chemical Industries, Ltd. Therapeutic composition for arthritis
WO1997009984A1 (en) * 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Immunosuppressant
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2001042218A1 (en) * 1999-12-13 2001-06-14 Kabushiki Kaisha Toyota Chuo Kenkyusho Quinoline derivatives and organic electroluminescent devices
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US6620939B2 (en) 2001-09-18 2003-09-16 General Electric Company Method for producing bisphenol catalysts and bisphenols
JP2006513848A (ja) * 2003-03-03 2006-04-27 ゼネラル・エレクトリック・カンパニイ ビスフェノール触媒及びビスフェノールの製造方法
US7432396B2 (en) * 2004-06-25 2008-10-07 Sumitomo Chemical Company, Limited Process for producing (Z)-1-phenyl-1-diethylaminocarbonyl-2-hydroxymethylcyclopropane
UY32743A (es) 2009-06-25 2010-12-31 Amgen Inc Compuestos heterocíclicos y sus usos
KR20130095772A (ko) 2010-10-05 2013-08-28 퍼듀 퍼머 엘피 나트륨 채널 차단제로서 퀴나졸린 화합물
AU2011329806A1 (en) * 2010-11-17 2013-05-30 Amgen Inc. Quinoline derivatives as PIK3 inhibitors
BR112015002950A2 (pt) * 2012-08-24 2017-08-08 Hoffmann La Roche novos derivados de bicíclico-piridina
US9815797B2 (en) 2013-12-09 2017-11-14 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of TNF activity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2134169A1 (en) * 1971-04-23 1972-12-08 Clin Byla Ets 3-acyl-4-substd - quinoline derivs - analgesics, antiinflammatories, diuretics
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS6165869A (ja) * 1984-09-07 1986-04-04 Kyowa Hakko Kogyo Co Ltd キノリン−ｎ−オキシド誘導体
NO174506B (no) * 1984-10-30 1994-02-07 Usv Pharma Corp Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
EP0259687B1 (en) * 1986-09-12 1991-07-03 American Cyanamid Company Method for the preparation of pyridine-2,3-dicarboxylic acids
GB8716971D0 (en) * 1987-07-17 1987-08-26 Pfizer Ltd Therapeutic agents
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US4968701A (en) * 1988-04-26 1990-11-06 E. I. Du Pont De Nemours And Company 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids
US5124325A (en) * 1989-06-13 1992-06-23 Kyorin Pharmaceutical Co., Ltd. Therapeutic agents of metabolic bone disease
DE3935491A1 (de) * 1989-10-25 1991-05-02 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-carbonylharnstoffe
JPH05506216A (ja) * 1990-04-10 1993-09-16 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 医薬としてのピリジン
DE4105551A1 (de) * 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE4129500A1 (de) * 1991-09-05 1993-03-11 Basf Ag Hochschlagzaehe, flammgeschuetzte polyphenylenether/polyamidformmassen
NO940245D0 (no) * 1993-01-28 1994-01-24 Takeda Chemical Industries Ltd Quinolin eller quinazolinderivater, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
EP0567107A1 (en) 1993-10-27
HU9301197D0 (en) 1993-07-28
AU656069B2 (en) 1995-01-19
CN1079222A (zh) 1993-12-08
NO931482L (no) 1993-10-25
HU211852A9 (en) 1995-12-28
AU3699193A (en) 1993-10-28
TW232013B (enExample) 1994-10-11
EP0567107B1 (en) 2001-11-21
HUT64322A (en) 1993-12-28
NO305973B1 (no) 1999-08-30
CA2094774A1 (en) 1993-10-25
FI931855A0 (fi) 1993-04-23
US5948782A (en) 1999-09-07
DE69331171T2 (de) 2002-07-11
ATE209199T1 (de) 2001-12-15
FI931855L (fi) 1993-10-25
DE69331171D1 (de) 2002-01-03
NZ247477A (en) 1995-07-26
FI931855A7 (fi) 1993-10-25
NO931482D0 (no) 1993-04-22
RU2130934C1 (ru) 1999-05-27

Similar Documents

Publication Publication Date Title
KR940005273A (ko) 퀴놀린 및 퀴나졸린 유도체를 함유하는 약학적 조성물 및 그의 신규 화합물
AU598491B2 (en) Pyridyl-methylthio substituted benzimidazoles
HRP20080236T3 (en) Quinoline derivatives as phosphodiesterase inhibitors
MX9203163A (es) Esteres morfolinoetilicos de acido micofenolico y composiciones.
PT533264E (pt) Processo para a preparacao de omeprazole
ATE126218T1 (de) Bis(acyloxymethyl)imidazol-derivate.
KR920021511A (ko) 신규의 n-알킬렌피페리디노 화합물 및 이의 거울상 이성질체 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR910019989A (ko) 비스-아릴 아미드 및 우레아 화합물들, 이들로 구성된 조성물 이들을 이용한 paf 억제 방법 및 이들의 생산 방법
PE20050480A1 (es) Acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il)alquil]fosfonico y derivados
KR870004981A (ko) 헤테로시클릭 옥소프탈라지닐 아세트산의 제조방법
JPH02178278A (ja) 心臓保護トコフェロール類似体
KR840008013A (ko) 퀴놀론 카복실산의 제조방법
ATE5141T1 (de) Xanthon- und thioxanthonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE37872T1 (de) Phenylinden-derivate, ihre salze, und verfahren zu ihrer herstellung.
ATE34394T1 (de) Therapeutisch aktive di-, tri-, tetra- und penta- aza-indene.
KR960022505A (ko) 신규한 5-피롤릴-6-할로게노-2-피리딜메틸설피닐벤즈이미다졸 유도체
DE68909855D1 (de) 2-[(4-Piperidinyl)methyl]-1,2,3,4-tetrahydroisochinolin-Derivate, ihre Herstellung und ihre therapeutische Verwendung.
KR930001414B1 (ko) 아졸 유도체와 그의 약제학적으로 허용가능한 염
KR900016937A (ko) 헤테로시클릭 화합물
KR890002291B1 (ko) 2-알킬벤즈이미다졸 유도체의 제조방법
EP0726269A4 (en) QUINOLINE CARBONIC ACID DERIVATIVE AND ITS SALTS
EA200101170A1 (ru) Галоидпроизводные 9-деоксо-9а-аза-9а-гомоэритромицина а
BRPI0210444B1 (pt) Stereo-relevant process for the preparation of nucleosidal analogs
FI903972A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 1-oksa-2-okso-8-atsaspiro/4,5/dekaanijohdannaisten valmistamiseksi
MX9100450A (es) Reduccion de niveles de acido urico en la sangre

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000